{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037979","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2026-08-14T11:35:47+00:00","discovered_at":"2026-08-14T11:40:00.529021+00:00","generated_at":"2026-08-14T11:40:32.458280+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lantern Pharma Q2 net loss $7.1M; LP-300 PFS benefit deepens; OMAI spin-off","bullets":["Q2 2026 net loss $7.1M ($0.57/share) vs $4.3M ($0.40) YoY; operating loss down 25% to $3.5M.","Cash $7.4M at June 30, 2026; raised $4.4M gross from May 14 registered direct offering.","LP-300 HARMONIC: median PFS 8.9 mo in L858R patients completing 6 cycles (n=9) vs 8.4 mo overall (n=16); HR 0.37; FDA cleared protocol amendments to focus on L858R and extend to 8 cycles.","EMA cleared LP-184 Phase 1b/2 bladder cancer trial at Rigshospitalet, Denmark; FDA cleared TNBC trial; USPTO Notice of Allowance for three-gene signature.","Open Medicine AI established as separate company with executed commercial licenses; plans to raise capital at OMAI level."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037979","json":"https://secwatch.observer/filing/0001493152-26-037979.json","markdown":"https://secwatch.observer/filing/0001493152-26-037979.md","text":"https://secwatch.observer/filing/0001493152-26-037979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226037979/0001493152-26-037979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226037979/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T11:40:32.458280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}